We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
AnaSpec Introduces new OVA GO™ Peptides
Product News

AnaSpec Introduces new OVA GO™ Peptides

AnaSpec Introduces new OVA GO™ Peptides
Product News

AnaSpec Introduces new OVA GO™ Peptides


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "AnaSpec Introduces new OVA GO™ Peptides"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Continuing to expand its collection of ready-to-go peptides, AnaSpec has released a new selection of OVA peptides in the GO™ peptide format.

Proteolytic processing of proteins in the cytoplasm generates peptide epitopes that are generally 8-10 amino acids in length. The binding of these peptides to the surface major histocompatibility complex (MHC) class I molecules and subsequent presentation to T-cells elicits an immune response. A model antigen extensively studied is Ovalbumin (OVA). OVA is processed to the presenting octapeptide (257-264), SIINFEKL, through proteasomal and non-proteasomal activities. As with peptides naturally presented by H-2Kb, SIINFEKL has on its 5th position an amino acid with an aromatic side chain (Phe) and on the 8th position, an aliphatic side chain (Leu).3 Variants of this peptide consisting of substituting different amino acids at strategic positions have yielded valuable information on the interaction of this peptide and the MHC complex.

The use of AnaSpec’s SIINFEKL has been reported in peer-reviewed journals since 1997. We are pleased that researchers have trusted us to provide this important peptide. We are also pleased to announce the recent release of variants of this peptide.
Advertisement